Atosiban as a potential treatment for endometriosis
Phase 2
Recruiting
- Conditions
- 10013326Endometrium outside of the uterus
- Registration Number
- NL-OMON47936
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 32
Inclusion Criteria
- Laparoscopic, MRI or ultrasound confirmed endometriosis
- Dysmenorrhea with painscore >=5 during menstrual period or withdrawal bleeding
- Age between 18 and 45 years old
Exclusion Criteria
- Inability to come to the hospital for the experiment
- Suspicion on a (post)menopausal state
- Continuous treatment with oral contraceptives or progestagens
- Current use of GnRh antagonist
- Current ovarian stimulation
- Current breastfeeding
- Labour or breastfeeding within the last 6 weeks
- Diagnosis of chronic pelvic pain
- Inability to give informed consent
- Language barrier
- Diabetes Mellitus, type I or II
- Hypersensitivity to atosiban or mannitol
- Use of systemic betamimetics
- Use of calcium channel blockers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Reduction in pain score on a visual analog scale</p><br>
- Secondary Outcome Measures
Name Time Method <p>Use of analgisics, experienced and observed side effects, oxytocin and<br /><br>prostaglandin serum levels before and after admission.</p><br>